A Nobel Laureate, a Stealth Biotech, and $87 Million Walk Into a Bar
A UK biotech with a Nobel laureate co-founder just emerged from seven years of stealth mode with $87 million and a plan to do what no approved drug can: remove the protein clumps already destroying patients' hearts. The investor syndicate behind the bet is stacked.
For seven years, Immutrin didn't exist. Not publicly, anyway.
The Cambridge, UK-based biotech was founded in 2019 by a team that includes a Nobel Prize winner and the guy who literally built the UK's national center for the disease they're trying to cure. They've been quietly working in stealth mode ever since, not saying a word to the outside world while they developed an antibody designed to do something no approved drug currently does: rip out the protein clumps already clogging your heart.
Last week, the silence broke. Immutrin emerged with an oversubscribed £65 million (roughly $87 million) Series A led by Frazier Life Sciences, with F-Prime Capital, Qiming Venture Partners, SR One, and founding backers Cambridge Innovation Capital and Cambridge Enterprise Ventures joining the round.
That's a lot of money for a company most people have never heard of. So what exactly convinced some of biotech's sharpest investors to write checks this big for a startup still in the preclinical stage?
The Disease That Slowly Turns Your Heart to Concrete
To understand Immutrin, you need to understand ATTR cardiomyopathy. It's a form of amyloidosis, a group of diseases where misfolded proteins (called amyloid fibrils) build up in your organs. Think of it like mineral deposits slowly clogging a pipe; except the pipe is your heart, and the deposits are made of a protein called transthyretin (TTR).
Over time, these fibrils accumulate in heart tissue, making the walls thick and stiff. The heart can't relax properly between beats. It can't fill with enough blood. Eventually, it fails.
Current treatments focus on stopping new fibrils from forming. Drugs like Pfizer's tafamidis stabilize the TTR protein so it doesn't misfold in the first place. That's useful, especially if you catch the disease early. But for patients who already have significant amyloid deposits built up in their hearts? Turning off the faucet doesn't unclog the drain.
That's the gap Immutrin is trying to fill.
Fighting Fire With Your Own Immune System
Immutrin's lead antibody doesn't just block new amyloid from forming. It's designed to Picture the difference between putting a "no littering" sign on a beach versus sending in a cleanup crew with trucks.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
actively remove the amyloid that's already there.
The mechanism works like this: the antibody latches onto amyloid fibrils sitting in heart tissue, then flags them for destruction by the body's own immune system. It's essentially painting a target on the enemy so your natural defenses know exactly where to strike. Professor Sir Mark Pepys, one of Immutrin's scientific founders, spent decades studying how to activate these natural clearance mechanisms. The antibody is the product of that lifelong obsession.
If it works, this approach could complement existing therapies beautifully. You'd use a stabilizer to stop new fibrils from forming while using Immutrin's antibody to clean up the mess that's already there. One drug turns off the faucet; the other unclogs the drain.
The $87 million will fund the antibody through clinical proof-of-concept studies. That means taking it from the lab into actual patients for the first time and seeing whether the science translates into real-world results.
The Founders Read Like a Biotech Hall of Fame
The scientific pedigree here is almost absurdly impressive.
Sir Gregory Winter won the 2018 Nobel Prize in Chemistry for his work on phage display, a technique that revolutionized how we discover and engineer antibodies. He co-founded some of the most important antibody companies in history: Cambridge Antibody Technology (CAT), Domantis (acquired by GSK), and Bicycle Therapeutics. If therapeutic antibodies had a Mount Rushmore, Winter's face would be on it.
Professor Sir Mark Pepys is an emeritus professor of medicine at University College London and the founder of the NHS National Amyloidosis Centre. He's not just an expert in this disease; he built the institution that treats it in the UK. His decades of research on immune-mediated amyloid clearance form the scientific backbone of Immutrin's entire approach.
Professor Daniel Christ, based at the Garvan Institute of Medical Research in Sydney, brings deep expertise in antibody display, humanization, and single-domain antibody technology. He rounds out a founding trio that collectively covers the disease biology, the antibody engineering, and the drug design.
Leading the company day-to-day is CEO Mihriban Tuna, an early employee at Domantis. Notice the pattern? She's worked alongside these founders before. That kind of continuity matters when you're building a company around complex science.
Why Frazier Went Big
Frazier Life Sciences doesn't mess around. The Palo Alto-based firm closed its twelfth venture fund at $1.3 billion in 2025 (oversubscribed, naturally), making it their largest fund ever. Since 2010, their portfolio companies have racked up over 65 FDA approvals and more than 60 IPOs or acquisitions. They've helped build companies like NewAmsterdam Pharma, Arcutis Biotherapeutics, and Alpine Immune Sciences (acquired by Vertex).
So when Frazier's managing partner James N. Topper takes a board seat at your stealth-mode biotech, it sends a signal. The firm isn't just writing a check; they're committing to build.
F-Prime Capital (the venture arm of Fidelity) joining as a co-lead carries its own weight. Add in Qiming Venture Partners and SR One (the venture arm historically connected to GlaxoSmithKline), and you've got a syndicate that knows drug development inside and out.
The round was oversubscribed, which means more investors wanted in than there was room for. In a market where early-stage fundraising remains highly selective, that's telling.
How $87 Million Stacks Up Right Now
Let's put this in context. Immutrin isn't your average biotech startup, and it isn't American.
Recent comparable Series A rounds in early 2026 include Mendra's $82 million raise for AI-driven rare disease therapies and Poplar Therapeutics pulling in $50 million for anti-IgE allergy treatments already in Phase 1. Immutrin's $87 million round sits at the upper end of this range, which is notable for a company with a preclinical asset.
The size reflects a few things: the strength of the founding team, the unmet medical need in ATTR cardiomyopathy, and the potential for the platform to expand into other types of amyloidosis beyond the lead program. When your scientific founders include a Nobel laureate and the person who literally wrote the book on amyloid clearance, investors tend to round up.
The Big "If"
Of course, nothing is guaranteed. Immutrin still needs to prove its antibody works in humans, not just in preclinical models. The jump from lab to clinic is where countless promising therapies have stumbled. Immune-mediated clearance sounds elegant on paper, but orchestrating the body's defenses to selectively remove amyloid deposits without causing harmful inflammation is a delicate balancing act.
There's also the competitive landscape to consider. ATTR cardiomyopathy has attracted serious attention from big pharma in recent years. Pfizer's tafamidis is already on the market. Alnylam and Ionis have RNA-based approaches in advanced development. Immutrin's "deplete what's already there" angle is differentiated, but the company will need to prove that clearing existing deposits translates into meaningful clinical improvement (better heart function, longer survival, improved quality of life) rather than just looking good on an imaging scan.
With $87 million, the company has enough runway to get to proof-of-concept data. That's the critical inflection point. If the early clinical results are clean, Immutrin will have no trouble raising again. If not, even a Nobel laureate on the cap table won't save them.
The Bottom Line
Immutrin's emergence from stealth is one of the more interesting biotech stories of early 2026. A world-class scientific team, a differentiated mechanism of action, top-tier investors, and a clear shot at a massive unmet need: it's the kind of combination that gets venture capitalists excited for good reason.
But the real story starts now. Seven years of quiet development got them to the launchpad. Clinical data will determine whether they actually reach orbit. The $87 million buys them a ticket to find out.
Deals & M&A4 min read
Merck Just Spent $6.7 Billion on a Drug Most People Have Never Heard Of
Merck is paying $6.7 billion for Terns Pharmaceuticals and its early-stage leukemia drug. With Keytruda's $29.5 billion in annual sales about to face patent expiration, this is what urgency looks like in pharma.
